# US 2024/0182923 A1 · Artificial expression constructs for modulating gene expression in claustrum neurons

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182923 A1
- Document ID: US20240182923A1
- Status: Published application
- Kind: A1
- Application number: 18/285,188
- Filed: 2022-03-30
- Published: 2024-06-06
- Earliest claimed: 2021-03-30
- Assignees: Allen Institute
- Applicants: Allen Institute
- Inventors: Tanya Daigle; Lucas T. Graybuck; Adriana Estela Sedeño Cortés; Bosiljka Tasic; Jonathan Ting
- Web page: https://patentgrep.com/patent/US20240182923A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used to express synthetic genes or modify gene expression in claustrum neurons including L6 IT Car3 neurons.

## Claims

### Claim 1

An artificial expression construct comprising (i) an MGT_E51 enhancer having the sequence as set forth in SEQ ID NO: 1 or a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 1; (ii) a promoter; and (iii) a heterologous coding sequence.

### Claim 2

A concatenated core of an eHGT_774m, eHGT_772m, or eHGT486m enhancer.

### Claim 3 (depends on 2)

The concatenated core of claim 2, wherein the concatenated core comprises the sequence as set forth in SEQ ID NO: 54, SEQ ID NO: 56, or SEQ ID NO: 58 or a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 54, SEQ ID NO: 56, or SEQ ID NO: 58.

### Claim 4 (depends on 2)

The concatenated core of claim 2, wherein the concatenated core comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the core of eHGT_774m, core of eHGT_772m, and/or core of eHGT486m.

### Claim 5 (depends on 2)

The concatenated core of claim 2, comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the sequence as set forth in SEQ ID NO: 54, SEQ ID NO: 56, and/or SEQ ID NO: 58 or a sequence having at least 90% sequence identity to the sequence as set forth in SEQ ID NO: 54, SEQ ID NO:
56, and/or SEQ ID NO: 58.

### Claim 6 (depends on 2)

The concatenated core of claim 2, having 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the sequence as set forth in SEQ ID NO: 54.

### Claim 7 (depends on 2)

The concatenated core of claim 2, having 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the sequence as set forth in SEQ ID NO: 56.

### Claim 8 (depends on 2)

The concatenated core of claim 2, having 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of the sequence as set forth in SEQ ID NO: 58.

### Claim 9 (depends on 6)

The concatenated core of claim 6, having 3 copies of the sequence as set forth in SEQ ID NO: 54.

### Claim 10 (depends on 7)

The concatenated core of claim 7, having3 copies of the sequence as set forth in SEQ ID NO:

### Claim 11 (depends on 8)

The concatenated core of claim 8, having 3 copies of the sequence as set forth in SEQ ID NO: 58.

### Claim 12 (depends on 9)

The concatenated core of claim 9, wherein the concatenated core has the sequence as set forth in SEQ ID NO: 55.

### Claim 13 (depends on 10)

The concatenated core of claim 10, wherein the concatenated core has the sequence as set forth in SEQ ID NO: 57.

### Claim 14 (depends on 11)

The concatenated core of claim 11, wherein the concatenated core has the sequence as set forth in SEQ ID NO: 59.

### Claim 15

An artificial expression construct comprising (i) an enhancer selected from MGT_E51, MGT_E52, MGT_E57, eHGT_770m, eHGT_774m, eHGT_772m, eHGT_486m, eHGT_875m, eHGT_923m, eHGT_924m, eHGT_925m, eHGT_926m, 3xcore2_eHGT_774m, 3xcore2_eHGT_772m, and/or 3xCore_eHGT486m; (ii) a promoter;
and (iii) a heterologous coding sequence.

### Claim 16 (depends on 15)

The artificial expression construct of claim 15, wherein the heterologous coding sequence encodes an effector element or an expressible element.

### Claim 17 (depends on 16)

The artificial expression construct of claim 16, wherein the effector element comprises a reporter protein or a functional molecule.

### Claim 18 (depends on 17)

The artificial expression construct of claim 17, wherein the reporter protein comprises a fluorescent protein.

### Claim 19 (depends on 17)

The artificial expression construct of claim 17, wherein the functional molecule comprises a functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or a designer receptor exclusively activated by designer drug (DREADD).

### Claim 20 (depends on 16)

The artificial expression construct of claim 16, wherein the expressible element comprises a non-functional molecule.

### Claim 21 (depends on 20)

The artificial expression construct of claim 20, wherein the non-functional molecule comprises a non-functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or DREADD.

### Claim 22 (depends on 15)

The artificial expression construct of claim 15, wherein the artificial expression construct is associated with a capsid that crosses the blood brain barrier.

### Claim 23 (depends on 22)

The artificial expression construct of claim 22, wherein the capsid comprises PHP.eB, AAV-BR1, AAV-PHP.S, AAV-PHP.B, or AAV-PPS.

### Claim 24 (depends on 15)

The artificial expression construct of claim 15, wherein the artificial expression construct comprises or encodes a skipping element.

### Claim 25 (depends on 24)

The artificial expression construct of claim 24, wherein the skipping element comprises a 2A peptide or an internal ribosome entry site (IRES).

### Claim 26 (depends on 25)

The artificial expression construct of claim 25, wherein the 2A peptide comprises T2A, P2A, E2A, or F2A.

### Claim 27 (depends on 15)

The artificial expression construct of claim 15, wherein the artificial expression construct comprises or encodes a set of features selected from: MGT_E51, MGT_E52, MGT_E57, eHGT_770m, eHGT_774m, eHGT_772m, eHGT_486m, eHGT_875m, eHGT_923m, eHGT_924m, eHGT_925m, eHGT_926m, 3xcore2_eHGT_774m, 3xcore2_eHGT_772m, 3xCore_eHGT486m, AAV, scAAV, rAAv, pAAV, minBglobin, CMV, minCMV, minRho, minRho*, fluorescent protein, Cre, iCre, dgCre, 10aa, nuclear localization protein, tag cassette, FlpO, tTA2, SP10, WPRE, WPRE3, hGHpA, and/or BGHpA.

### Claim 28 (depends on 15)

The artificial expression construct of claim 15, wherein the artificial expression construct comprises or encodes a set of features selected from:
MGT_E51-[minimal promoter]-[heterologous coding sequence]-WPRE-hGHpA;
MGT_E52-[minimal promoter]-[heterologous coding sequence]-WPRE-hGHpA;
MGT_E57-[minimal promoter]-[heterologous coding sequence]-WPRE-hGHpA;
eHGT_770m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_774m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_772m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_486m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
MGT_E52-[minimal promoter]-[heterologous coding sequence]-hGHpA;
eHGT_875m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_923m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_924m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_925m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
eHGT_926m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
3xCore_eHGT486m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
3xcore2_eHGT_774m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
3xcore2_eHGT_772m-[minimal promoter]-[heterologous coding sequence]-WPRE3-BGHpA;
MGT_E51-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
MGT_E52-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
MGT_E57-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_770m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_774m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_772m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_486m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_875m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_923m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_924m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_925m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements];
eHGT_926m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements]; or
3xCore_eHGT486m-[minimal promoter]-[heterologous coding sequence]-[post-regulatory elements].

### Claim 29 (depends on 15)

A vector comprising an artificial expression construct of claim 15.

### Claim 30 (depends on 29)

The vector of claim 29, wherein the vector comprises a viral vector.

### Claim 31 (depends on 30)

The vector of claim 30, wherein the viral vector comprises a recombinant adeno-associated viral (AAV) vector.

### Claim 32

An adeno-associated viral (AAV) vector comprising at least one heterologous coding sequence, wherein the heterologous coding sequence is under the transcriptional control of a promoter and an enhancer selected from MGT_E51, MGT_E52, MGT_E57, eHGT_770m, eHGT_774m, eHGT_772m, eHGT_486m, eHGT_875m, eHGT_923m, eHGT_924m, eHGT_925m, eHGT_926m, 3xcore2_eHGT_774m, 3xcore2_eHGT_772m, and 3xCore_eHGT486m.

### Claim 33 (depends on 32)

The AAV vector of claim 32, wherein the heterologous coding sequence encodes an effector element or an expressible element.

### Claim 34 (depends on 33)

The AAV vector of claim 33, wherein the effector element comprises a reporter protein or a functional molecule.

### Claim 35 (depends on 34)

The AAV vector of claim 34, wherein the reporter protein comprises a fluorescent protein.

### Claim 36 (depends on 34)

The AAV vector of claim 34, wherein the functional molecule comprises a functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or DREADD.

### Claim 37 (depends on 33)

The AAV vector of claim 33, wherein the expressible element comprises a non-functional molecule.

### Claim 38 (depends on 37)

The AAV vector of claim 37, wherein the non-functional molecule comprises a non-functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or DREADD.

### Claim 39 (depends on 15, 29)

A transgenic cell comprising an artificial expression construct of claim 15 and/or a vector of claim 29.

### Claim 40 (depends on 39)

The transgenic cell of claim 39, wherein the transgenic cell is a claustrum neuron.

### Claim 41 (depends on 40)

The transgenic cell of claim 40, wherein the transgenic cell is an L6 IT Car3 neuron.

### Claim 42 (depends on 39)

The transgenic cell of claim 39, wherein the transgenic cell is murine, human, or non-human primate.

### Claim 43 (depends on 15, 29, 39)

A non-human transgenic animal comprising an artificial expression construct of claim 15, a vector of claim 29, and/or a transgenic cell of claim 39.

### Claim 44 (depends on 43)

The non-human transgenic animal of claim 43, wherein the non-human transgenic animal is a mouse or a non-human primate.

### Claim 45 (depends on 15, 32, 39)

An administrable composition comprising an artificial expression construct of claim 15, a vector of claim 32, and/or a transgenic cell of claim 39.

### Claim 46 (depends on 15, 29, 39, 43)

A kit comprising an artificial expression construct of claim 15, a vector of claim 29, a transgenic cell of claim 39, and/or a non-human transgenic animal of claim 43.

### Claim 47 (depends on 45)

A method for expressing a gene within a population of cells in vivo or in vitro, the method comprising providing the administrable composition of claim 45 in a sufficient dosage and for a sufficient time to a sample or subject comprising the population of cells thereby expressing the gene within the population of cells.

### Claim 48 (depends on 47)

The method of claim 47, wherein the gene encodes an effector element or an expressible element

### Claim 49 (depends on 48)

The method of claim 48, wherein the effector element comprises a reporter protein or a functional molecule.

### Claim 50 (depends on 49)

The method of claim 49, wherein the reporter protein comprises a fluorescent protein.

### Claim 51 (depends on 49)

The method of claim 49, wherein the functional molecule comprises a functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or DREADD.

### Claim 52 (depends on 51)

The method of claim 51, wherein the receptor is a serotonin receptor.

### Claim 53 (depends on 52)

The method of claim 52, wherein the serotonin receptor is a HTR2a receptor.

### Claim 54 (depends on 48)

The method of claim 48, wherein the expressible element comprises a non-functional molecule.

### Claim 55 (depends on 52)

The method of claim 52, wherein the non-functional molecule comprises a non-functional ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channelrhodopsin, CRISPR/CAS molecule, editase, guide RNA molecule, microRNA, homologous recombination donor cassette, or DREADD.

### Claim at position 56



### Claim 56 (depends on 55)

The method of claim 55, wherein the non-functional receptor is a non-functional serotonin receptor.

### Claim 57 (depends on 56)

The method of claim 56, wherein the non-functional serotonin receptor is a non-functional HTR2a receptor.

### Claim 58 (depends on 47)

The method of claim 47, wherein the gene comprises or encodes a molecule that reduces HTR2a expression.

### Claim 59 (depends on 47)

The method of claim 47, further comprising administering a psychedelic drug.

### Claim 60 (depends on 59)

The method of claim 59, wherein the psychedelic drug comprises psilocybin; psilocin; lysergic acid diethylamide (LSD; N,N-dimethyltryptamine (DMT); mescaline; 5-MeO-DMT; 5-Methoxy-diisopropyltryptamine (5-MeO-DIPT); dipropyltryptamine (DPT), 2C-T-7, 2,5-dimethoxy-4-methylamphetamine (DOM), 2,5-dimethoxy-4-bromoamphetamine (DOB), 2,5-Dimethoxy-4-iodoamphetamine (DOI), or 2C-I

### Claim 61 (depends on 47)

The method of claim 47, wherein the providing comprises pipetting.

### Claim 62 (depends on 61)

The method of claim 61, wherein the pipetting is to a brain slice.

### Claim 63 (depends on 62)

The method of claim 62, wherein the brain slice comprises a claustrum neuron.

### Claim 64 (depends on 63)

The method of claim 63, wherein the brain slice comprises an L6 IT Car3 neuron.

### Claim 65 (depends on 62)

The method of claim 62, wherein the brain slice is murine, human, or non-human primate.

### Claim 66 (depends on 47)

The method of claim 47, wherein the providing comprises administering to a living subject.

### Claim 67 (depends on 66)

The method of claim 66, wherein the living subject is a human, non-human primate, or a mouse.

### Claim 68 (depends on 66)

The method of claim 66, further comprising evaluating the living subject for an effect of the psychedelic drug.

### Claim 69 (depends on 68)

The method of claim 68, wherein the effect of the psychedelic drug is a change in mood, alertness, or attention.

### Claim 70 (depends on 66)

The method of claim 66, wherein the administering to a living subject is through injection.

### Claim 71 (depends on 71)

The method of claim 71, wherein the injection comprises intravenous injection, intraparenchymal injection into brain tissue, intracerebroventricular (ICV) injection, intra-cisterna magna (ICM) injection, or intrathecal injection.

### Claim 72

An artificial expression construct consisting of or consisting essentially of a sequence as set forth in SEQ ID NO: 41, SEQ ID NO: 69, SEQ ID NO: 42, SEQ ID NO:43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 68, SEQ ID NO:70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or SEQ ID NO: 79 or a sequence having at least 90% sequence identity to a sequence as set forth in SEQ ID NO: 41, SEQ ID NO: 69, SEQ ID NO: 42, SEQ ID NO:43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 68, SEQ ID NO:70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or SEQ ID NO: 79.
